Scientists hunt for weaknesses in pancreatic Cancer's fuel system
NCT ID NCT07664891
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is analyzing tissue and blood samples from 64 people with pancreatic cancer that has spread. Researchers want to understand how cancer cells change their energy use and interact with surrounding cells. The goal is to find new targets for treatment and better ways to predict which therapies will work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could identify new drug targets and biomarkers to predict treatment response in pancreatic cancer.
- What could go wrong
- This is an early-stage observational study, not a treatment trial. It may not lead directly to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Paoli-Calmettes
RECRUITINGMarseille, 13009, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- New drug combo aims to tackle deadly pancreatic cancer
- New hope for hard-to-treat pancreatic cancer: targeted drug combo enters phase 3 trial
- Last-Resort drug access opens for advanced pancreatic cancer patients
- New combo therapy targets Hard-to-Treat cancers
- New pill plus chemo aims to tackle tough pancreatic cancer